Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 279

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

Open access
Smith, Bryan D., Kaufman, Michael D., Lu, Wei-Ping, Gupta, Anu, Leary, Cynthia B., Wise, Scott C., Rutkoski, Thomas J., Ahn, Yu Mi, Al-Ani, Gada, Bulfer, Stacie L., Caldwell, Timothy M., Chun, Lawrence, Ensinger, Carol L., Hood, Molly M., McKinley, Arin, Patt, William C., Ruiz-Soto, Rodrigo, Su, Ying, Telikepalli, Hanumaiah, Town, Ajia, Turner, Benjamin A., Vogeti, Lakshminarayana, Vogeti, Subha, Yates, Karen, Janku, Filip, Abdul Razak, Albiruni Ryan, Rosen, Oliver, Heinrich, Michael C., Flynn, Daniel L.·2019·Cancer Cell

Abstract

Ripretinib (DCC-2618) was designed to inhibit the full spectrum of mutant KIT and PDGFRA kinases found in cancers and myeloproliferative neoplasms, particularly in gastrointestinal stromal tumors (GISTs), in which the heterogeneity of drug-resistant KIT mutations is a major challenge. Ripretinib is a "switch-control" kinase inhibitor that forces the activation loop (or activation "switch") into an inactive conformation. Ripretinib inhibits all tested KIT and PDGFRA mutants, and notably is a type II kinase inhibitor demonstrated to broadly inhibit activation loop mutations in KIT and PDGFRA, previously thought only achievable with type I inhibitors. Ripretinib shows efficacy in preclinical cancer models, and preliminary clinical data provide proof-of-concept that ripretinib inhibits a wide range of KIT mutants in patients with drug-resistant GISTs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2019.04.006

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Cited by

See all 279

Metadata

Authors
Smith, B. D., Kaufman, M. D., Lu, W.-P., Gupta, A., Leary, C. B., Wise, S. C., Rutkoski, T. J., Ahn, Y. M., Al-Ani, G., Bulfer, S. L., Caldwell, T. M., Chun, L., Ensinger, C. L., Hood, M. M., McKinley, A., Patt, W. C., Ruiz-Soto, R., Su, Y., Telikepalli, H., Town, A., Turner, B. A., Vogeti, L., Vogeti, S., Yates, K., Janku, F., Abdul Razak, A. R., Rosen, O., Heinrich, M. C., & Flynn, D. L.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2019-05
Volume
35
Issue
5
Pages
738-751.e9
ISSN
1535-6108 (ISSN-L)
OpenAlex
W2946078866
Cited by
279
References
56
FWCI
27.75
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. https://app.cochat.ai/papers/10.1016/j.ccell.2019.04.006
The paper
Smith, B. D., Kaufman, M. D., Lu, W.-P., Gupta, A., Leary, C. B., Wise, S. C., Rutkoski, T. J., Ahn, Y. M., Al-Ani, G., Bulfer, S. L., Caldwell, T. M., Chun, L., Ensinger, C. L., Hood, M. M., McKinley, A., Patt, W. C., Ruiz-Soto, R., Su, Y., Telikepalli, H., . . . Flynn, D. L. (2019). Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer Cell. https://doi.org/10.1016/j.ccell.2019.04.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.